Hans Jürgen Hoffmann

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • S Bank, Denmark
  • P S Andersen, Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark., Denmark
  • J Burisch, Department of Gastroenterology, Herlev Hospital, Herlev, Denmark.
  • ,
  • N Pedersen, Department of Gastroenterology, Herlev Hospital, Herlev, Denmark., Denmark
  • S Roug, Department of Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.
  • ,
  • J Galsgaard, Medical Department, Køge Hospital, Køge, Denmark.
  • ,
  • S Y Turino, Medical Department, Hillerød Hospital, Hillerød, Denmark.
  • ,
  • J B Brodersen, Medical Department, Sydvestjysk Hospital, Esbjerg, Denmark., Denmark
  • S Rashid, Medical Department, Bispebjerg Hospital, Bispebjerg, Denmark.
  • ,
  • B K Rasmussen, Medical Department, Nykøbing Falster Hospital, Nykøbing Falster, Denmark., Denmark
  • S Avlund, Medical Department V, Aarhus University Hospital, Aarhus, Denmark.
  • ,
  • T.B. Olesen, Medical Department, Slagelse Hospital, Slagelse, Denmark., Denmark
  • H J Hoffmann
  • Marianne Kragh Thomsen
  • V Ø Thomsen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark., Denmark
  • M Frydenberg
  • B A Nexø
  • J Sode, University of Southern Denmark, Statens Serum Institut, University of Copenhagen
  • ,
  • U Vogel, National Research Centre for the Working Environment, Copenhagen, Denmark, Denmark
  • V Andersen, University of Southern Denmark, Denmark

Antitumor necrosis factor-α (TNF-α) is used for treatment of severe cases of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). However, one-third of the patients do not respond to the treatment. Genetic markers may predict individual response to anti-TNF therapy. Using a candidate gene approach, 39 mainly functional single nucleotide polymorphisms (SNPs) in 26 genes regulating inflammation were assessed in 738 prior anti-TNF-naive Danish patients with IBD. The results were analyzed using logistic regression (crude and adjusted for age, gender and smoking status). Nineteen functional polymorphisms that alter the NFκB-mediated inflammatory response (TLR2 (rs3804099, rs11938228, rs1816702, rs4696480), TLR4 (rs5030728, rs1554973), TLR9 (rs187084, rs352139), LY96 (MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094)), TNF-α signaling (TNFA (TNF-α) (rs361525), TNFRSF1A (TNFR1) (rs4149570), TNFAIP3(A20) (rs6927172)) and other cytokines regulated by NFκB (IL1B (rs4848306), IL1RN (rs4251961), IL6 (rs10499563), IL17A (rs2275913), IFNG (rs2430561)) were associated with response to anti-TNF therapy among patients with CD, UC or both CD and UC (P⩽0.05). In conclusion, the results suggest that polymorphisms in genes involved in activating NFκB through the Toll-like receptor (TLR) pathways, genes regulating TNF-α signaling and cytokines regulated by NFκB are important predictors for the response to anti-TNF therapy among patients with IBD. Genetically strong TNF-mediated inflammatory response was associated with beneficial response. In addition, the cytokines IL-1β, IL-6 and IFN-γ may be potential targets for treating patients with IBD who do not respond to anti-TNF therapy. These findings should be examined in independent cohorts before these results are applied in a clinical setting.The Pharmacogenomics Journal advance online publication, 29 April 2014; doi:10.1038/tpj.2014.19.

Original languageEnglish
JournalPharmacogenomics Journal
Pages (from-to)526–534
Number of pages9
Publication statusPublished - 29 Apr 2014

See relations at Aarhus University Citationformats

ID: 79639852